Protagonist Therapeutics (NASDAQ:PTGX) Raised to “Strong-Buy” at Wall Street Zen

by · The Markets Daily

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Several other analysts also recently commented on PTGX. Wolfe Research began coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price for the company. Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Friday, July 17th. Barclays increased their price target on Protagonist Therapeutics from $119.00 to $151.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $110.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

Check Out Our Latest Analysis on Protagonist Therapeutics

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $136.11 on Friday. Protagonist Therapeutics has a 1 year low of $50.49 and a 1 year high of $143.29. The firm has a 50-day moving average of $116.79 and a two-hundred day moving average of $101.45. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of -75.20 and a beta of 1.79.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The business had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. Research analysts expect that Protagonist Therapeutics will post 3.69 earnings per share for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Bryan Giraudo sold 36,000 shares of Protagonist Therapeutics stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $100.14, for a total transaction of $3,605,040.00. Following the completion of the transaction, the director owned 27,825 shares in the company, valued at approximately $2,786,395.50. The trade was a 56.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the sale, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at $52,410,617.36. This represents a 12.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 161,130 shares of company stock worth $16,355,220. Insiders own 5.19% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its position in Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares during the last quarter. Greenline Wealth Management LLC purchased a new position in Protagonist Therapeutics during the 4th quarter worth $27,000. Osaic Holdings Inc. boosted its holdings in Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after acquiring an additional 525 shares during the last quarter. Hantz Financial Services Inc. grew its stake in shares of Protagonist Therapeutics by 222.4% in the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after acquiring an additional 656 shares in the last quarter. Finally, Canton Hathaway LLC bought a new stake in shares of Protagonist Therapeutics in the 4th quarter worth $87,000. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.

Featured Stories